Plus Therapeutics unit wins Medicare enrollment approval for CNSide diagnostic lab
PUBT · 1d ago
Share
Listen to the news
- Plus Therapeutics unit CNSide Diagnostics received Medicare enrollment approval from CMS, securing a Provider Transaction Access Number for its CNSide CSF Assay Platform.
- Status enables Medicare claim submissions for the platform, including tumor cell enumeration testing, subject to coverage determinations by the relevant Medicare Administrative Contractor.
- Company expects CMS to set a Clinical Laboratory Fee Schedule payment rate for new CPT code 0640U effective July 1, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070730PRIMZONEFULLFEED9715114) on May 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved